Other languages Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
31.58 ^USD	-9.44%		+2.13%	+423.71%

Jul. 02	Evercore ISI Raises Price Target on Longboard Pharmaceuticals to $80 From $57, Keeps Outperform Rating	MT
Jul. 01	Longboard Pharmaceuticals Gets FDA Breakthrough Therapy Designation for Seizure Treatment	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Longboard Pharmaceuticals Gets FDA Breakthrough Therapy Designation for Seizure Treatment	Jul. 01
Longboard Pharmaceuticals, Inc. Receives Breakthrough Therapy Designation for Bexicaserin	Jul. 01
Longboard Pharmaceuticals, Inc. Announces Positive Interim Results from Its Ongoing 52-Week Open-Label Extension of the Pacific Study Evaluating Bexicaserin	Jun. 10
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12
Longboard Pharmaceuticals Closes $242 Million Public Offering	Jan. 08
Longboard Pharmaceuticals Prices $210 Million Stock Offering	Jan. 04
Longboard Pharmaceuticals Launching Share Offering	Jan. 02
Sector Update: Health Care Stocks Gain Late Afternoon	Jan. 02
Longboard Pharmaceuticals Shares Surge After Positive Topline Results for Seizures Treatment	Jan. 02
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Jan. 02
Top Midday Gainers	Jan. 02
Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin in Participants with Developmental and Epileptic Encephalopathies	Jan. 02
Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers	Nov. 29
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Longboard Completes Enrollment in Study of LP352 for Treatment of Developmental, Epileptic Encephalopathies	23-08-23
Longboard Pharmaceuticals, Inc. Completes Enrollment of Phase 1b/2a Pacific Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies	23-08-23
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Other languages

Filters